PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33126251-6 2021 AMPK activators-notably berberine and the butyric acid produced by health-promoting microflora-are also beneficial in this regard, as are soy isoflavones, which function as selective agonists for ERbeta. Berberine 24-33 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 0-4 32445451-2 2020 Here we summarized the energy sensor adenosine 5"-monophosphate (AMP)-activated protein kinase (AMPK) and its agonist berberine can combat the common underlying pathological events of neurodegeneration including oxidative stress, neuroinflammation, mitochondrial disorder, glutamate excitotoxicity, apoptosis, autophagy disorder and neurovascular units disruption. Berberine 118-127 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 96-100 33130557-3 2021 While studying pharmaceutical agents that can target beta-catenin in cancer cells, we observed that the plant compound berberine (BBR), a potent activator of AMP-activated protein kinase (AMPK), can reduce beta-catenin expression and downstream signaling in HCC cells in a dose dependent manner. Berberine 119-128 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 158-186 33130557-3 2021 While studying pharmaceutical agents that can target beta-catenin in cancer cells, we observed that the plant compound berberine (BBR), a potent activator of AMP-activated protein kinase (AMPK), can reduce beta-catenin expression and downstream signaling in HCC cells in a dose dependent manner. Berberine 119-128 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 188-192 33130557-3 2021 While studying pharmaceutical agents that can target beta-catenin in cancer cells, we observed that the plant compound berberine (BBR), a potent activator of AMP-activated protein kinase (AMPK), can reduce beta-catenin expression and downstream signaling in HCC cells in a dose dependent manner. Berberine 130-133 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 158-186 33130557-3 2021 While studying pharmaceutical agents that can target beta-catenin in cancer cells, we observed that the plant compound berberine (BBR), a potent activator of AMP-activated protein kinase (AMPK), can reduce beta-catenin expression and downstream signaling in HCC cells in a dose dependent manner. Berberine 130-133 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 188-192 33130557-4 2021 More in depth analyses to understand the mechanism revealed that BBR-induced reduction of beta-catenin occurs independently of AMPK activation, and does-not involve transcriptional or post-translational mechanisms. Berberine 65-68 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 127-131 32969153-5 2020 The present review aimed to clarify determinant cellular and molecular targets of berberine in RA and found that berberine through modulating several signalling pathways involved in the joint inflammation, including PI3K/Akt, Wnt1/beta-catenin, AMPK/lipogenesis and LPA/LPA1 /ERK/p38 MAPK can inhibit inflammatory proliferation of FLS cells, suppress DC activation and modulate Th17/Treg balance and thus prevent cartilage and bone destruction. Berberine 113-122 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 245-249 30902523-7 2020 These beneficial properties of berberine are mediated in part through its ability to target multiple signaling pathways, including PKA, p38 MAPK, Wnt/beta-catenin, AMPK, RANK/RANKL/OPG, PI3K/Akt, NFAT, NF-kappaB, Hedgehog, and oxidative stress signaling. Berberine 31-40 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 164-168 32353823-6 2020 Other mechanism ascribed to Berberine are related to its inhibition of hepatic gluconeogenesis through the Phospheoenolpyruvate carboxykinase (PEPCK), Glucose-6-phosphate (G6Pase) and AMP-activated protein kinase (AMPK). Berberine 28-37 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 184-212 32353823-6 2020 Other mechanism ascribed to Berberine are related to its inhibition of hepatic gluconeogenesis through the Phospheoenolpyruvate carboxykinase (PEPCK), Glucose-6-phosphate (G6Pase) and AMP-activated protein kinase (AMPK). Berberine 28-37 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 214-218 35301252-0 2022 Ferulic acid and berberine, via Sirt1 and AMPK, may act as cell cleansing promoters of healthy longevity. Berberine 17-26 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 42-46 35301252-9 2022 Hence, it is proposed that ferulic acid may exert complementary or synergistic health-promoting effects when used in conjunction with clinically useful AMPK activators, such as the nutraceutical berberine. Berberine 195-204 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 152-156 32445451-3 2020 The above actions of berberine may mainly depend on activating AMPK and its downstream targets such as mammalian target of rapamycin (mTOR), sirtuin1 (SIRT1) , nuclear factor erythroid-2 related factor-2 (Nrf2), nuclear factor-kappaB (NF-kappaB), phosphoinositide 3-kinase / protein kinase B (PI3K/Akt), nicotinamide adenine dinucleotide (NAD+ ), and p38 mitogen-activated protein kinase (p38 MAPK). Berberine 21-30 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 63-67 30304866-9 2018 The complex paradigm will be discussed within the context of if/how dietary components, nutrients including fatty acids and non-nutrient food components, such as resveratrol, berberine, curcumin and the flavonoid genistein, modulate AMPK dependent processes relating to inflammation and metabolism. Berberine 175-184 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 233-237 32789786-7 2020 As the second achievement of this review, among the signaling pathways through which berberine regulates intracellular processes, AMP-activated protein kinase (AMPK) has a central and critical role, showing that enhancing activity of AMPK pathway can be considered as a promising therapeutic approach for atherosclerosis treatment. Berberine 85-94 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 130-158 32789786-7 2020 As the second achievement of this review, among the signaling pathways through which berberine regulates intracellular processes, AMP-activated protein kinase (AMPK) has a central and critical role, showing that enhancing activity of AMPK pathway can be considered as a promising therapeutic approach for atherosclerosis treatment. Berberine 85-94 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 160-164 32789786-7 2020 As the second achievement of this review, among the signaling pathways through which berberine regulates intracellular processes, AMP-activated protein kinase (AMPK) has a central and critical role, showing that enhancing activity of AMPK pathway can be considered as a promising therapeutic approach for atherosclerosis treatment. Berberine 85-94 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 234-238 30129983-5 2018 Preincubation at high glucose concentration followed by moderate-glucose incubation activated the AMPK pathway, but the activation was abolished with berberine or metformin treatment. Berberine 150-159 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 98-102 30129983-6 2018 In contrast, alteration from normal glucose to moderate glucose concentration in the medium suppressed AMPK activity, which was activated by berberine or metformin. Berberine 141-150 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 103-107 30129983-8 2018 In conclusion, AMPK activated by glucose reduction is inhibited by berberine or metformin. Berberine 67-76 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 15-19 30129983-10 2018 The potent glucose-lowering effects with minimal hypoglycemia of berberine and metformin may be partially due to their bidirectional regulation of the AMPK signaling pathway. Berberine 65-74 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 151-155 28847510-8 2017 Our studies provide novel insight into potential approaches to treatment of FOP, since several AMPK activators (e.g. metformin, berberine, and aspirin) are already in clinical use for the treatment of diabetes and metabolic syndromes. Berberine 128-137 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 95-99